Evotec Says Sandoz Deal Is ‘Validation’ Of Biologics Ambitions

Chief Business Officer Matthias Evers Talks Biologics Technology Platform And Access

12 Jul 2023

In the aftermath of announcing a major collaboration with Sandoz on biosimilars, Evotec’s chief business officer Matthias Evers speaks about how the deal provides “validation” of Just-Evotec’s technology platform, while also outlining the firm’s wider ambitions to enable more efficient development of and broader access to biologics.

Matthias Evers, Evotec’s chief business officer — Matthias Evers is Evotec’s chief business officer • Source: Evotec

In a major deal for the off-patent industry, Sandoz recently announced a multi-year collaboration with Evotec subsidiary Just-Evotec Biologics that will see the firms develop and manufacture multiple biosimilars together.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Rising Leaders 2025: Kevin Parker On Climbing Toward Breakthroughs In Biotech

22 Apr 2025

• By Meredith Landry

Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.

‘I Want Everything To Go Faster’: Medidata’s CEO On Pushing The Strategic Accelerator

17 Apr 2025

• By Jo Shorthouse

Appointed CEO 12 months ago, Anthony Costello wasted no time in orchestrating strategic change at Medidata. He talked to In Vivo about the art of the pivot and how to constantly push boundaries.

From Brain Waves to Better Outcomes: Inside Alto Neuroscience’s Biomarker Strategy

16 Apr 2025

• By David Wild

Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.